Clinical Trials Logo

Amphetamine-related Disorders clinical trials

View clinical trials related to Amphetamine-related Disorders.

Filter by:

NCT ID: NCT03318081 Recruiting - Clinical trials for Amphetamine Addiction

The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction

Start date: October 20, 2017
Phase: N/A
Study type: Interventional

The computerized cognitive rehabilitation therapy will be used to treat amphetamine-type stimulant (ATS) addiction.

NCT ID: NCT03221283 Not yet recruiting - Clinical trials for Amphetamine Addiction

The Application of Music Therapy in Female Amphetamine Use Disorder

Start date: November 30, 2017
Phase: N/A
Study type: Interventional

The group music therapy will be used to treat female amphetamine-type stimulant (ATS) addiction

NCT ID: NCT02952196 Suspended - Clinical trials for Amphetamine Addiction

Cannabioids as a New Intervention for Amphetamine Dependence

Start date: March 2018
Phase: Phase 2
Study type: Interventional

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder. The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

NCT ID: NCT02950376 Not yet recruiting - Clinical trials for Amphetamine Addiction

The Novel Addiction Assessment Study in Synthetic Drugs Addiction

Start date: December 2016
Phase: N/A
Study type: Observational

The purpose of this research is to develop an objective assessment based on the virtual reality techniques which is used for evaluate addiction severity.

NCT ID: NCT02836756 Not yet recruiting - Clinical trials for Amphetamine Addiction

Cannabidiol as a New Intervention for Amphetamine Dependence

Start date: October 2016
Phase: Phase 2
Study type: Interventional

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). Cannabidiol (CBD), the second most abundant component of cannabis, is known for its broad spectrum of physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly CBD has been shown to be potentially helpful in treating addiction, due to its effects on various neuronal circuits involved in this disorder. Our overall hypothesis is that CBD is an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

NCT ID: NCT02797990 Completed - Pregnancy Clinical Trials

Conflict Between Maternal Autonomy and Child Health in Substance-use

Start date: May 2016
Phase: N/A
Study type: Observational

Qualitative project, comprising open-ended semi-structured interviews with healthcare workers, who provide antenatal care to substance-using women.

NCT ID: NCT02774954 Active, not recruiting - HIV Clinical Trials

Change the Cycle: An RCT to Prevent Injection Initiation

CTC
Start date: June 2016
Phase: Phase 3
Study type: Interventional

The study will test the efficacy of a hour long, one-on-one, active listening counseling session (called Change the Cycle or CTC) aimed at reducing behaviors among active people who inject drugs (PWID) that research has found to facilitate uptake of injection drug use among non-injectors. The study will involve ~1,100 PWID who will be randomized to CTC or an equal attention control intervention on improving nutrition. Participants will be recruited in Los Angeles and San Francisco, California and followed up at 6 and 12 months to determine changes in direct and indirect facilitation of injection initiation among non-injectors.

NCT ID: NCT02713815 Recruiting - Clinical trials for Amphetamine Addiction

Novel Intervention for Amphetamine-type Stimulants Addiction

Start date: July 2016
Phase: N/A
Study type: Interventional

The motivational-cognitive psychotherapy and repetitive transcranial magnetic stimulation (rTMS) will be used to treat amphetamine-type stimulant (ATS) addiction.

NCT ID: NCT02541526 Recruiting - Heroin Dependence Clinical Trials

Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia

Start date: May 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate tolerability, acceptability and potential efficacy of 4 months of maintenance treatment with Mirtazapine as compared to placebo for patients with co-occurring amphetamine-type stimulant and opioid dependence (COATS) receiving buprenorphine maintenance treatment (BMT) in Kota Bharu.

NCT ID: NCT02541513 Active, not recruiting - Heroin Dependence Clinical Trials

An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence

Start date: May 2013
Phase: Phase 3
Study type: Interventional

The proposed study will evaluate the tolerability, acceptability and potential efficacy of paliparidone for the treatment of co-occurring opioid and amphetamine-type stimulant (ATS) dependence. In the proposed clinical trial, all patients will first discontinue illicit opioid and ATS and be inducted onto buprenorphine maintenance treatment (BMT) in the inpatient ward at the department of psychiatry before beginning to receive paliparidone. Tolerability and acceptability will be evaluated by assessing the rates of patient retention during treatment, patient satisfaction with treatment and adverse effects during treatment. The potential efficacy of paliparidone will be evaluated with regard to the primary outcome measure: reductions in illicit ATS use, based on urine toxicology testing and self-report. Secondary outcome measures include treatment retention, reduction in HIV risk behaviors and improvements in functional status.